111 related articles for article (PubMed ID: 29877745)
1. Osteoprotegerin increases parallel to insulin resistance in obese adolescents.
Kotanidou EP; Kotanidis CP; Giza S; Serbis A; Tsinopoulou VR; Karalazou P; Tzimagiorgis G; Galli-Tsinopoulou A
Endocr Res; 2019; 44(1-2):9-15. PubMed ID: 29877745
[TBL] [Abstract][Full Text] [Related]
2. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
[TBL] [Abstract][Full Text] [Related]
3. The association of insulin resistance with serum osteoprotegerin in obese adolescents.
Suliburska J; Bogdanski P; Gajewska E; Kalmus G; Sobieska M; Samborski W
J Physiol Biochem; 2013 Dec; 69(4):847-53. PubMed ID: 23695991
[TBL] [Abstract][Full Text] [Related]
4. Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.
Erazmus M; Rumińska M; Witkowska-Sędek E; Kucharska AM; Stelmaszczyk-Emmel A; Majcher A; Pyrżak B
Front Endocrinol (Lausanne); 2022; 13():963467. PubMed ID: 36060948
[TBL] [Abstract][Full Text] [Related]
5. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity.
Ugur-Altun B; Altun A; Gerenli M; Tugrul A
Diabetes Res Clin Pract; 2005 Jun; 68(3):217-22. PubMed ID: 15936463
[TBL] [Abstract][Full Text] [Related]
6. Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths.
Zampetti S; Lucantoni F; Pacifico L; Campagna G; Versacci P; Pierimarchi P; Buzzetti R
J Endocrinol Invest; 2019 Apr; 42(4):427-434. PubMed ID: 30132289
[TBL] [Abstract][Full Text] [Related]
7. Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction.
Karavanaki K; Tsouvalas E; Vakaki M; Soldatou A; Tsentidis C; Kaparos G; Augoulea A; Alexandrou A; Lambrinoudaki Ι
J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1169-1177. PubMed ID: 30352039
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.
Buzi F; Maccarinelli G; Guaragni B; Ruggeri F; Radetti G; Meini A; Mazzolari E; Cocchi D
Clin Endocrinol (Oxf); 2004 Jan; 60(1):87-91. PubMed ID: 14678293
[TBL] [Abstract][Full Text] [Related]
9. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
10. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.
Pacifico L; Andreoli GM; D'Avanzo M; De Mitri D; Pierimarchi P
World J Gastroenterol; 2018 May; 24(19):2073-2082. PubMed ID: 29785076
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.
Oh ES; Rhee EJ; Oh KW; Lee WY; Baek KH; Yoon KH; Kang MI; Yun EJ; Park CY; Choi MG; Yoo HJ; Park SW
Metabolism; 2005 Jan; 54(1):49-54. PubMed ID: 15562379
[TBL] [Abstract][Full Text] [Related]
12. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
Pepene CE; Ilie IR; Marian I; Duncea I
Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study.
Gannagé-Yared MH; Yaghi C; Habre B; Khalife S; Noun R; Germanos-Haddad M; Trak-Smayra V
Eur J Endocrinol; 2008 Mar; 158(3):353-9. PubMed ID: 18299469
[TBL] [Abstract][Full Text] [Related]
14. Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.
Erol M; Bostan Gayret O; Tekin Nacaroglu H; Yigit O; Zengi O; Salih Akkurt M; Tasdemir M
Iran Red Crescent Med J; 2016 Nov; 18(11):e41873. PubMed ID: 28203453
[TBL] [Abstract][Full Text] [Related]
15. Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women.
Ugur-Altun B; Altun A
Arch Med Res; 2007 Nov; 38(8):891-6. PubMed ID: 17923273
[TBL] [Abstract][Full Text] [Related]
16. The Bone Markers Sclerostin, Osteoprotegerin, and Bone-Specific Alkaline Phosphatase Are Related to Insulin Resistance in Children and Adolescents, Independent of Their Association with Growth and Obesity.
Stanik J; Kratzsch J; Landgraf K; Vogel M; Thiery J; Kiess W; Körner A
Horm Res Paediatr; 2019; 91(1):1-8. PubMed ID: 30904905
[TBL] [Abstract][Full Text] [Related]
17. A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance.
O'Sullivan EP; Ashley DT; Davenport C; Penugonda L; Kelleher G; Devlin N; Crowley R; O'Shea P; Agha A; Thompson CJ; O'Gorman DJ; Smith D
Metabolism; 2013 Jan; 62(1):34-8. PubMed ID: 22841521
[TBL] [Abstract][Full Text] [Related]
18. Circulating osteoprotegerin in postmenopausal osteoporotic women: marker of impaired glucose regulation or impaired bone metabolism.
Mashavi M; Menaged M; Shargorodsky M
Menopause; 2017 Nov; 24(11):1264-1268. PubMed ID: 28697041
[TBL] [Abstract][Full Text] [Related]
19. Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin/RANKL in prediabetic patients.
Bilgir O; Yavuz M; Bilgir F; Akan OY; Bayindir AG; Calan M; Bozkaya G; Yuksel A
Minerva Endocrinol; 2018 Mar; 43(1):19-26. PubMed ID: 28146138
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
